Pneumococcal 21-valent Conjugate Vaccine, PNEUMOCOCCUS, PURIFIED POLYSACCHARIDES ANTIGEN clinical trials

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older

This study is testing a new vaccine (V116) for pneumonia in adults aged 50 and over. We want to see how safe it is, how well people tolerate it, and if it helps their immune system fight off pneumonia germs compared to an existing vaccine.